Sanofi-aventis Announces Final Results of Zentiva Offer
Sanofi-aventis holds about 96.8% of share capital
Sanofi-aventis Europe’s shareholding in Zentiva N.V. satisfies the statutory 95% threshold for a squeezeout procedure of remaining minority shareholders in accordance with the applicable provisions of Dutch law. Sanofi-aventis intends to initiate such a procedure in the near future.
“I am personally very pleased to announce the successful outcome of our offer to acquire Zentiva and I am looking forward to welcoming the Zentiva employees into the sanofi-aventis group. Zentiva brings a large portfolio of branded generic drugs and affordable medicines, which is well adapted to market dynamics and patients needs in this region”, said Chris Viehbacher, CEO of sanofi-aventis.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.